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AbsTrACT
Objectives Pain is a very common symptom of juvenile 
idiopathic arthritis (JIA). Disease activity alone cannot 
explain symptoms of pain in all children, suggesting 
other factors may be relevant. The objectives of this 
study were to describe the different patterns of pain 
experienced over time in children with JIA and to identify 
predictors of which children are likely to experience 
ongoing pain.
Methods This study used longitudinal-data from 
patients (aged 1–16 years) with new-onset JIA. 
Baseline and up to 5-year follow-up pain data from 
the Childhood Arthritis Prospective Study (CAPS) were 
used. A two-step approach was adopted. First, pain 
trajectories were modelled using a discrete mixture 
model. Second, multinomial logistic regression was used 
to determine the association between variables and 
trajectories.
results Data from 851 individuals were included 
(4 years, median follow-up). A three-group trajectory 
model was identified: consistently low pain (n=453), 
improved pain (n=254) and consistently high pain 
(n=144). Children with improved pain or consistently 
high pain differed on average at baseline from 
consistently low pain. Older age at onset, poor function/
disability and longer disease duration at baseline were 
associated with consistently high pain compared with 
consistently low pain. Early increases in pain and poor 
function/disability were also associated with consistently 
high pain compared with consistently low pain.
Conclusions This study has identified routinely 
collected clinical factors, which may indicate those 
individuals with JIA at risk of poor pain outcomes earlier 
in disease. Identifying those at highest risk of poor pain 
outcomes at disease onset may enable targeted pain 
management strategies to be implemented early in 
disease thus reducing the risk of poor pain outcomes.
InTrOduCTIOn
Inflammatory arthritis in children is a chronic and 
often disabling disease. With an annual incidence of 
approximately 33/100 000 children, juvenile idio-
pathic arthritis (JIA) represents the most common 
form of inflammatory arthritis in children.1 The 
disease is heterogeneous,2 its course variable with 
periods of activity and remission3 and can severely 
reduce quality of life.2 4 5 Up to a third of young 
people report active disease progressing into adult 
life.6 
Pain is a commonly reported symptom in JIA7 8 
and a recent study of illness perceptions in adoles-
cents with JIA found that beliefs about their disease 
activity was influenced by their experience of pain.9 
A study of individuals with polyarticular JIA found 
that pain was reported almost daily, with 31% 
reporting severe pain.10 Such levels of pain interfere 
with physical, educational, emotional and social 
activity, even when disease activity is controlled.11 12 
Moreover, a significant number of patients continue 
to report pain into adulthood.13 This may explain 
the emerging consensus that the management of JIA 
needs to address more than active inflammation14 
to minimise the long-term impact of the disease.
Active disease, although influential,15–17 accounts 
for small amounts of variance in pain in patients 
with JIA.15 18 Considerable variance in pain remains 
unaccounted for and increases as the disease 
progresses into adulthood.4 We know little about 
the different possible patterns of pain in JIA over 
time or which factors predict them. Previous studies 
What is already known on this topic?
 ► Juvenile idiopathic arthritis (JIA) is the most 
common form of inflammatory arthritis in 
children and young people.
 ► Pain is one of the most common symptoms 
reported by children and young people with JIA.
 ► Pain in JIA is poorly understood and 
unsatisfactorily managed for children and 
young people.
What this study adds?
 ► Children with JIA classify into three pain groups: 
consistently low pain, improved pain and 
consistently high pain. A clinically significant 
proportion of patients experience high pain that 
persists.
 ► Factors at presentation including age at onset, 
disease duration, functional disability and pain 
are identified as associated with consistently 
high pain over time.
 ► This study will help identify children at the 
highest risk of chronic pain, who should be 
targeted early with multidisciplinary pain 
management interventions.
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were limited in their ability to provide greater understanding 
due to the nature and extent of the data collected, being either 
cross-sectional data or longitudinal data with small samples.19 20 
They also focused on examining relationships between variables 
(variable-centred analyses). The aims of this analysis are to iden-
tify and group children with similar patterns of pain over time 
from baseline (person-centred analysis), and thereby predict 
patients with JIA at risk of poor pain outcomes .21
MeThOd
study population
The participants in this study were recruited to the Childhood 
Arthritis Prospective Study (CAPS). This longitudinal prospec-
tive inception cohort study of individuals with new-onset inflam-
matory arthritis, primarily JIA, was established in 2001, in the 
UK. Methodological details of this study have been published 
elsewhere.22 Patients are recruited into CAPS at first presenta-
tion to paediatric rheumatology (baseline). Written informed 
consent was provided by parent(s)/guardian(s) and patients (aged 
16 years and older) in accordance with the Declaration of 
Helsinki.
data collection
Data items used in the present analysis included the 10 cm pain 
visual analogue scale (VAS) (580 proxy reports and 271 child 
reports), active joint count (AJC) from 71 joints, 10 cm physi-
cian’s global assessment (PGA) VAS, 10 cm patient/proxy general 
evaluation (PGE) VAS, Child Health Assessment Questionnaire 
(CHAQ: functional disability) scored 0–3, Moods and Feel-
ings Questionnaire (MFQ) scored 0–66 (self-report) and 0–68 
(proxy-report) and the physician-assigned International League 
Against Rheumatism (ILAR) subtype. In addition, this analysis 
also included medication taken in the first year (eg, disease- 
modifying antirheumatic drugs (DMARDs), biologics and 
steroids). Data included in the analysis were collected at base-
line (presentation), 6 months, 1 year and then annually up to 
5 years. The data were extracted from hospital records and 
questionnaires.
Analysis
The primary outcome measure was the 10 cm pain VAS scores. 
Only children with a JIA subtype recorded at year 1 and pain 
scores recorded at baseline plus at least one additional follow-up 
pain score (up to 5 years postbaseline) were included in the anal-
ysis. A two-stage approach to this analysis was used.23 First, pain 
trajectories of patients were modelled using a form of discrete 
mixture-modelling called group-based trajectory analysis 
(GBTA).24 GBTA assigns each individual to a trajectory group, 
based on Bayesian posterior probabilities for group member-
ship.21 Group-based trajectories were modelled in groups 
ranging from two to six trajectories. The optimal number of 
possible trajectories was determined by statistical fit (including 
Bayesian information criterion and model parsimony21) and the 
clinical relevance determined by the research team.
In the second step, multivariable multinomial logistic regres-
sion models were used to determine the association between 
possible predictors and membership in the trajectory groups.23 25 
Predictors were chosen based on their salience to JIA and paedi-
atric pain. They included baseline measures of age at onset, 
gender, pain, AJC, PGA, PGE, CHAQ, MFQ and disease dura-
tion (at baseline), plus early change measures of pain, AJC, PGA, 
PGE, CHAQ and medication. The predictors were entered into 
the model simultaneously. To deal with missing covariate data 
(table 1), multiple imputation (chained equations26) was used, 
with 50 datasets generated using the rule of thumb that the 
minimum number of imputations equated to the percentage of 
incomplete cases.26 Data analysis was conducted using STATA 
V.12.0, and user-written STATA modules Kwallis2 and TRAJ.27
resulTs
study population
In total, 851 patients were included in this analysis. The median 
age at diagnosis was 7.6 years (IQR 3.6, 11.8), the median 
age at disease onset was 6.6 years (IQR 2.7, 10.8) and median 
disease duration at presentation was 5.3 months (IQR 2.7, 10.7) 
(table 1); 66% were female. The most common ILAR subtype 
recorded at 1 year was persistent oligoarthritis (n=265, 42.7%) 
(table 2). There were negligible differences in characteristics 
between those who were included and excluded from this anal-
ysis (see online supplementary table 1).
Trajectory model
The three-group model of pain (figure 1) was selected as the 
most clinically and statistically satisfactory (see online supple-
mentary table 2). Over 78% of children had a >0.7 probability 
of membership in their assigned trajectory groups. The aver-
aged posterior probabilities of group membership for each of 
the subgroups were all high (>0.8) with the smallest trajectory 
group representing 17% of the study population.
The largest group in the three-trajectory model was ‘consis-
tently low’ pain, which accounted for half of the participants in 
this analysis (figure 1). This consisted of a horizontal trajectory 
undulating around the 1 cm point of the pain VAS (starting at 
1.8 cm) throughout the 5-year period. The second group was 
‘improved pain’, which accounted for almost a third of partic-
ipants. This trajectory (starting at 5.5 cm) illustrated dramatic 
improvement in pain in the first year of follow-up, leading to a 
plateau for the subsequent 4 years. The third trajectory (starting 
at 4.9 cm) was ‘consistently high’ pain, which again was broadly 
horizontal, oscillating around the 5 cm point of the pain VAS 
throughout the 5-year follow-up.
Trajectory group characteristics
Subgroup analysis illustrated clear differences on average 
(median) between low persistent pain and the other pain trajec-
tories across the majority of covariates (table 1). On average 
(median), older age at onset, older age at baseline, baseline pain, 
longer disease duration at baseline and early changes in PGE, 
pain and CHAQ, distinguished between trajectories with consis-
tently high pain and improved pain (table 1).
Overall, 17% of the study cohort was in the consistently high 
pain group, this increased to approximately 25% for extended 
oligoarthritis (n=8, 24.2%), polyarthritis RF+ (n=6, 26.1%) 
and psoriatic arthritis (n=14, 26.9%) patients, and over 30% 
for children with enthesitis-related arthritis (n=10, 30.3%). 
While 42.7% of the study cohorts were classified with persistent 
oligoarthritis, this increased to over half of the children in 
the consistently low pain group and down to approximately 
one-third of the children in each of the other two groups.
Multinomial logistic regression
Variables associated with improved pain when compared with 
consistently low pain included being female, and longer disease 
duration, higher PGE and higher pain at baseline (table 3). In 
addition, associated early change factors included increased PGE 
in first 6 months, and increased CHAQ and pain in the first year 
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(table 3). When comparing consistently high pain with consis-
tently low pain, baseline factors of older age at onset, longer 
disease duration, higher PGE, higher CHAQ and higher pain 
were associated with consistently high pain membership, along 
with early change factors including treatment with biologics in 
the first year, increased PGE in the first 6 months and increased 
CHAQ and pain in the first year (table 3). Finally, when 
comparing consistently high pain with improved pain, the base-
line factors of older age at onset and higher CHAQ were asso-
ciated with consistently high pain, along with the early change 
factors of increased PGE in the first 6 months, and increased 
CHAQ and pain in the first year (table 3).
dIsCussIOn
Using GBTA, relatively novel in paediatric research, three distinct 
trajectories of pain in children and young people with JIA have 
been identified. Although a majority of children report low pain 
or pain which improves quickly during the first year following 
diagnosis, almost a fifth of children reported consistently high 
Table 1 Characteristics of the study population as a whole (n=851) and stratified by pain trajectory
Variable
Available data,
n (% missing) All patients
Consistently low pain,
n=453 (50.2%)
Improved pain,
n=254 (31.9%)
Consistently high pain,
n=144 (17.9%)
Baseline
  Age, years* 847 (0.5) 7.6 (3.6–11.8) 6.3 (2.9–10.9)†‡ 8.6 (3.7–12.3)†§ 10.8 (6.5–13.2)‡§
  Age at onset, years* 843 (0.9) 6.6 (2.7–10.8) 5.6 (2.4–9.9)†‡ 7.0 (3.0–11.1)†§ 9.3 (4.5–11.8)‡§
Gender n (%¶) 851 (0.0)
  Female 562 (66.0) 288 (63.6)** 184 (72.4)** 90 (62.5)**
  Male 289 (34.0) 165 (36.4) 70 (27.6) 54 (37.5)
Disease duration, months* 839 (1.4) 5.3 (2.7–10.7) 4.7 (2.3–8.5)†‡ 5.8 (2.8–12.8) †§ 6.9 (3.7–17.6)‡§
Disease duration from referral, weeks* 793 (6.8) 4 (1.3–7.7) 4 (1.4–7.7) 3.4 (1–7.1) 4.6 (1.3–8.1)
PGA, cm* 600 (29.5) 3 (1.8, 5.4) 2.6 (1.4, 4.8)†‡ 3.5 (2, 5.7)† 3.3 (2.1, 5.8)‡ 
AJC* 780 (8.3) 2 (1–6) 2 (1, 5)†‡ 3 (1, 8)† 3 (1, 8)‡
PGE, cm* 834 (2.0) 2.1 (0.5, 5) 0.8 (0.1, 2.4)†‡ 4.6 (2.2, 6.2)† 4.1 (2, 6.35)‡
Pain, cm* 851 (0.0) 3 (0.8, 5.7) 1 (0.2, 2.5)†‡  6 (4.5, 7.4)†§ 5 (3, 6.9)‡§
CHAQ* 849 (0.2) 0.6 (0.1–1.4) 0.3 (0–0.9)†‡ 1.1 (0.6–1.8)† 1.1 (0.6–1.8)‡
MFQ* 312 (63.3) 13 (6, 23) 9 (4, 16) 17 (9, 27) 21 (13, 27)
Early change
DMARDs 1st year n (%¶) 851 (0.0)
  No 434 (51) 274 (60.5)** 101 (39.8)** 59 (41.0)**
  Yes 417 (49) 179 (39.5) 153 (60.2) 85 (59.0)
Number of DMARDs 1st year n (%¶) 851 (0.0)
  1 381 (91.4) 169 (94.4)** 141 (92.2)** 71 (83.5)**
  2 31 (7.4) 8 (4.5) 10 (6.5) 13 (15.3)
  3 5 (1.2) 2 (1.1) 2 (1.3) 1 (1.2)
Biologics 1st year n (%¶) 851 (0.0)
  No 769 (90.4) 430 (94.9)** 222 (87.4)** 117 (81.3)**
  Yes 82 (9.6) 23 (5.1) 32 (12.6) 27 (18.7)
Number of biologics 1st year n (%¶) 851 (0.0)
  1 75 (91.5) 22 (95.6) 28 (87.5) 25 (92.6)
  2 6 (7.3) 1 (4.4) 3 (9.4) 2 (7.4)
  3 1 (1.2) 0 (0) 1 (3.1) 0 (0.0)
All steroids 1st year n (%¶) 851 (0.0)
  No 207 (24.3) 118 (26.1) 56 (22.1) 33 (22.9)
  Yes 644 (75.7) 335 (73.9) 198 (77.9) 111 (77.1)
Change in AJC 6 months, cm*†† 541 (36.4) −1 (−4, 0) −1 (−3, 0) −1 (−5, 0) −1 (−4, 0)
Change in PGA 6 months, cm*†† 390 (54.2) −1.9 (−3.9, –0.5) −1.9 (−4.2, –0.7) −1.9 (−3.4, –0.3) −1.8 (−3.9, –0.2)
Change in PGE 6 months, cm*†† 500 (41.2) −0.5 (–2.4, 0.3) −0.3 (–0.2, 0.1) −1.2 (–3.5, 0.6)§ −0.1 (–2, 1.5)§
Change in CHAQ 1 year*†† 702 (17.7) −0.1 (–0.6, 0) −0.1 (–0.6, 0)†‡ −0.4 (–1, 0)†§ 0 (–0.5, 0.4)‡§
Change in pain 1 year, cm*†† 691 (18.8) −0.7 (–3.2, 0.2) −0.4 (–1.9, 0)†‡ −3.2 (–5.8, –0.3)†§ 0.5 (–1.7, 2.6)‡§ 
All values are median (IQR) unless stated.
*Multiple comparisons of significant differences between trajectory groups using an adjusted P≤0.0083 from Kruskal-Wallis tests. n, number of children.
†Improved pain versus consistently low pain.
‡Consistently high pain versus consistently low pain.
§Consistently high pain versus improved pain.
¶Column.; PGA, Physician’s global assessment PGE, Parent’s/patient’s general evaluation of wellbeingwell-being VAS, visual analogue scale; CHAQ, Childhood Health Assessment 
Questionnaire.
**P≤0.05 from χ2 indicates a significant difference in proportions between the three trajectory groups.
††Minus denotes a decrease in the covariate.
AJC, active joint count; CHAQ, Childhood Health Assessment Questionnaire; n, number of children; nr, not reported; ns, non-significant; PGA, Physician’s Global Assessment; PGE, 
parent’s/patient’s general evaluation of well-being; VAS, visual analogue scale. 
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levels of pain over time. Pain at presentation is by far the stron-
gest, but not only predictor of consistently high pain, consistent 
with previous research.20 28 Neither AJC nor PGA at presenta-
tion, nor early changes in AJC or PGA, were found to predict 
membership in either of the three trajectory groups. Conse-
quently, a management approach focused primarily on disease 
activity may not necessarily lead to improvements in long-term 
pain. Children with consistently high pain were more likely to 
have been prescribed DMARDs and biologics compared with 
those in the other pain trajectories within the first 5 year of 
follow-up (see online supplementary table 3). This is consistent 
with findings reported by others that a significant proportion of 
patients with JIA treated with biologics including anti-TNF treat-
ments still experienced pain12 29 with 19% of patients reporting 
severe pain.30 Similarly, this study found that being treated with 
biologics within the first year almost trebled a child’s likelihood 
of consistently high pain membership. Clinicians must address 
disease activity in their treatment decisions but must also address 
factors such as pain when considering the best management 
approach for JIA.31
A notable finding was that baseline measures of disease activity 
such as the AJC and PGA, did not predict children’s membership 
in any pain trajectory group. In contrast, baseline evaluations 
of patients or proxy (CHAQ, PGE and pain) scores did inform 
membership in the pain trajectories, as did early changes in those 
measures. Baseline functional disability (CHAQ) was a strong 
predictor of membership of the consistently high pain trajectory. 
Packham and Hall in their cross-sectional study found that func-
tional disability contributed 18% of total variance explained in 
pain.4 Interestingly, an analysis of the CAPS cohort after a 1-year 
prospective follow-up found baseline pain to be a predictor 
of moderate-to-severe functional disability.32 These findings 
demonstrate the complex relationships between pain and func-
tional disability, with experiences of one likely to contribute to 
the self-report of the other.
Age at onset also appears to have a relationship with trajec-
tory group membership. Patients with consistently low pain 
were younger on average, those with improved pain were more 
commonly in the middle childhood age group at onset and 
those with consistently high pain were, on average, approaching 
early adolescence.14 Malleson et al16 and Weiss et al found that 
older age was predictive of pain in patients with JIA.14 Patients 
who are older at onset may find it more difficult to adjust with 
the changes to their functioning than younger children33 and 
perceive the long-term consequences of JIA as more significant.34 
Moreover, they may have to relearn and adjust to new ways 
of doing things rather than learning to do things for the first 
time as younger-onset children.35 Additionally, the psycholog-
ical, social and emotional pressures experienced by those whose 
disease starts in adolescence such as conforming to peer-group 
expectations, increasing independence and burgeoning identity 
may magnify their experience of pain and functional disability 
when compared with those whose disease starts when they are 
younger.35
Disease duration at baseline was also associated with consis-
tently high pain. One explanation for this may be due to the greater 
potential damage caused by JIA prior to its remission in consis-
tently high pain owing to potential delays in appropriate treat-
ment22 (with 21% of patients in this study waiting ≥1 year prior 
to presentation). Fantini et al found attaining remission decreases 
in proportion to delay in presenting to paediatric rheumatology.3 
Oen et al found that time between onset and diagnosis was a 
prospective predictor of functional disability at follow-up.5 
Parent’s unfamiliarity with the urgency of symptoms may delay 
seeking medical advice22; complicated by variables such as socio-
economic status.36 Therefore, their disease may go untreated 
for longer allowing functional disability to increase,22 poten-
tially demonstrating why poor functional disability predicted 
consistently high pain. This may also lead to a greater proba-
bility of enhanced sensitivity to all pain-inducing stimuli beyond 
Table 2 Distribution of year 1 physician-assigned ILAR subtypes stratified by pain trajectory, n=851
Variable All patients n (%)
Consistently low pain,
n=453 (50.2%)
Improved pain,
n=254 (31.9%)
Consistently high pain,
n=144 (17.9%) P value
Subtype at 1 year 620 317 (51.1) 198 (31.9) 105 (16.9) 0.001*
Systemic 39 (6.3) 16 (5.1)† (41.0) 17 (8.6)† (43.6) 6 (5.7)† (15.4)
Oligoarthritis (persistent) 265 (42.7) 165 (52.1)† (62.3) 64 (32.3)† (24.2) 36 (34.3)† (13.6)
Oligoarthritis (extended) 33 (5.3) 11 (3.5)† (33.3) 14 (7.1)† (42.4) 8 (7.6)† (24.2)
Polyarthritis (RF–) 158 (25.5) 75 (23.7)† (47.5) 59 (29.8)† (37.3) 24 (22.9)† (15.2)
Polyarthritis (RF+) 23 (3.7) 4 (1.3)† (17.4) 13 (6.6)† (56.5) 6 (5.7)† (26.1)
Enthesitis-related arthritis 33 (5.3)  13 (4.1)† (39.4) 10 (5.1)† (30.3) 10 (9.5)† (30.3)
Psoriatic arthritis 52 (8.4) 22 (6.9)† (42.3) 16 (8.1)† (30.8) 14 (13.3)† (26.9)
Undifferentiated 17 (2.7) 11 (3.5)† (64.7) 5 (2.5)† (29.4) 1 (1.0)† (5.9)
All values are n (column %) unless stated.
*P≤0.05 from χ2.
† % is for row.
ILAR, International League Against Rheumatism; RF, rheumatoid factor.
Figure 1 Pain trajectories from baseline to 5-year follow-up. VAS, 
visual analogue scale.
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that induced by affected joints.7 This amplification in pain may 
persist beyond the resolution of inflammation leading to periph-
eral and central sensitisation,7 and lowered pain thresholds, pain 
tolerances37 and high chronic pain, as found in those in consis-
tently high pain.
Contrary to previous research, depression was not found to 
predict any pain trajectory.28 38 In this study, depression was 
correlated positively with pain (see online supplementary table 
4). An explanation for the findings may be that PGE, which is a 
measure of well-being, occupies similar variance associated with 
depression, thereby reducing its uniquely associated contribu-
tion. Higher PGE scores were found to predict consistently high 
pain. Patients and/or their parents more readily view pain as an 
indicator of arthritis9 39 than do clinicians. Therefore, PGE scores 
would provide a more accurate indicator of pain experiences 
over time than PGA, as it takes into account pain experience.
The findings from this study have a number of implica-
tions for pain management in children presenting for the first 
time to paediatric rheumatology. Alongside objective markers 
of disease activity, this study suggests that clinicians should 
ensure that pain is also addressed, particularly among those 
presenting with higher levels of pain and PGE, poor func-
tional ability, older onset and/or longer disease duration. 
Importantly, early increases in PGE, poor functional ability 
and pain are also independently associated with consistently 
high pain, indicating that delays in pain management may 
only serve to increase the risk of a child developing consis-
tently high pain. Hence, pain management should be prior-
itised early in children with JIA. Furthermore, medications 
such as DMARDs, biologics and steroids, which are used to 
reduce disease activity, may be less efficacious in reducing 
pain in some patients. Therefore, an integrated management 
approach in which pain is assessed and managed alongside 
disease activity is needed to reduce the prospect of poor long-
term pain outcomes.
limitations
These findings must be viewed in the context of some limita-
tions. The pain, PGE, CHAQ and MFQ score was reported by a 
parent for children under the age of 11 and were self-reported 
by children aged ≥11 years. The potential limitations of such 
strategies of data collection have been identified previously.40 
However, this strategy reflects the routine collection of data in 
the UK paediatric rheumatology. Therefore, the baseline covari-
ates in this study correspond with data that were available to 
paediatric rheumatologists. Furthermore, information on pain 
management was not examined, which may highlight that if 
interventions were used they were not adequate in reducing pain 
in at least a fifth of the cohort.
COnClusIOn
This study has used clinical data which are routinely collected from 
patients with JIA to classify pain trajectories into three categories. 
Factors which contributed to pain patterns included disease features 
(eg, duration, age at onset, etc), which would enable children with 
JIA at an increased risk of consistently high pain over time to be 
identified early in disease. It is important for children with JIA 
that integrated pain management strategies are used in addition 
to pharmacological therapy aimed to control inflammation, and 
Table 3 Association between variables and pain trajectories from a multivariable multinomial logistic regression using 50 multiple imputed 
datasets (n=851)
Variable
relative risk ratio (95% CI)
Improved versus Consistently low Consistently high versus consistently low Consistently high versus improved
Baseline
Gender (base: female)
  Male 0.5 (0.3 to 0.9)* 0.7 (0.4 to 1.4) 1.5 (0.9 to 2.5)
Age at onset, per year 1.1 (0.99 to 1.1) 1.1 (1.1 to 1.2)* 1.1 (1.0 to 1.2)*
PGA, per cm 1.1 (0.9 to 1.3) 1.1 (0.9 to 1.3) 1.0 (0.8 to 1.2)
Disease duration, per month 1.02 (1.0 to 1.04)* 1.03 (1.0 to 1.1)* 1.0 (0.99 to 1.0)
AJC, per joint 0.9 (0.8 to 1.1) 0.95 (0.8 to 1.1) 1.0 (0.9 to 1.1)
PGE, per cm 1.3 (1.0 to 1.5)* 1.4 (1.1 to 1.7)* 1.1 (0.9 to 1.3)
CHAQ, per 0.125 1.1 (0.96 to 1.1) 1.2 (1.0 to 1.3)* 1.1 (1.0 to 1.2)*
Pain, per cm 3.2 (2.5 to 4.1)* 3.1 (2.4 to 4.0)* 1.0 (0.8 to 1.1)
MFQ, per 5% 1.3 (0.7 to 2.5) 1.3 (0.6 to 2.8) 1.0 (0.6 to 1.7)
Early change
DMARDs in 1st year (base: no)
  Yes 1.2 (0.7 to 2.1) 0.8 (0.4 to 1.5) 0.6 (0.4 to 1.1)*
Biologics in 1st year (base: no)
  Yes 2.3 (0.8 to 6.1) 3.0 (1.0 to 8.8)* 1.3 (0.7 to 2.6)
Steroids in 1st year (base: no)
  Yes 1.0 (0.5 to 1.9) 1.4 (0.7 to 3.1) 1.4 (0.8 to 2.6)
Change in AJC in 1st 6 months, per joint increase 0.9 (0.8 to 1.1) 1.0 (0.8 to 1.1) 1.0 (0.9 to 1.1)
Change in PGA in 1st 6 months, per cm increase 1.2 (0.9 to 1.4) 1.1 (0.9 to 1.4) 1.0 (0.8 to 1.2)
Change in PGE in 1st 6 months, per cm increase 1.3 (1.1 to 1.5)* 1.4 (1.2 to 1.7)* 1.1 (1.0 to 1.3)*
Change in CHAQ in 1st year, per 0.125 increase 1.1 (1.01 to 1.2)* 1.2 (1.1 to 1.3)* 1.1 (1.0 to 1.1)*
Change pain in 1st year, per cm increase 1.4 (1.2 to 1.7)* 1.7 (1.4 to 2.1)* 1.2 (1.1 to 1.3)*
*P≤0.05.
CHAQ, Childhood Health Assessment Questionnaire; DMARDs, disease-modifying antirheumatic drugs; MFQ, Moods and Feelings Questionnaire; PGA, Physician’s Global 
Assessment;PGE, parent’s/patient’s general evaluation.
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targeted at those most at risk, as soon as possible after diagnosis to 
improve important long-term pain outcomes.
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